With more than 2,750 hospital accounts and 117,000 ACCU-CHEK Inform systems in use in more than 48 countries, Roche leads in the world wide hospital blood glucose market. The system is expected to be available in the U.S. In 2011 a total of 25.8 million adults and children in the U.S. The US is the world’s key market in hospital blood glucose testing. healthcare professionals new capabilities to help ensure the accuracy of test results, streamline data communications and provide optimal patient care.” “ACCU-CHEK systems have been proven in hospitals around the world and this next-generation wireless system sets a new standard by offering U.S.

“Accuracy and patient safety are the foremost concerns for blood glucose testing in hospitals and other point-of-care settings,” said Roland Diggelmann, chief operating officer at Roche Diagnostics. The system utilizes new patented technology to deliver improved accuracy and enables automatic real-time wireless transfer of patient data between hospital medical staff and the laboratory. The ACCU-CHEK Inform II system offers healthcare professionals the first truly wireless hospital blood glucose device.

Food and Drug Administration (FDA) for the ACCU-CHEK Inform II system, a next-generation blood glucose monitor for hospital point-of-care testing.

Roche (SIX: RO, ROG OTCQX: RHHBY) announced today that it has received clearance from the U.S.

Accu chek inform ii meter